Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

by Shapira-Frommer, Ronnie , Arkhipov, Alexander , Colombo, Nicoletta , Monk, Bradley J , Li, Kan , Salman, Pamela , Dubot, Coraline , Samouëlian, Vanessa , Castonguay, Vincent , Caceres, M. Valeria , Yañez, Eduardo , Olivera Hurtado de Mendoza, Mivael , Toker, Sarper , Hoyos Usta, Edwin , Tewari, Krishnansu S , Gümüş, Mahmut , Hasegawa, Kosei , Keefe, Stephen M , Lorusso, Domenica

in Adult / Adverse events / Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / Apoptosis / Bevacizumab / Cancer therapies / Carcinoma - drug therapy / Carcinoma - mortality / Carcinoma - secondary / Cervical cancer / Cervix / Chemotherapy / Death / Double-Blind Method / Female / Gynecologic Oncology / Gynecology / Hematology / Humans / Hypotheses / Immunotherapy / Intention to Treat Analysis / Laboratories / Metastases / Metastasis / Middle Aged / Monoclonal antibodies / Neoplasm Staging / Neutropenia / Obstetrics / Oncology / Patient Reported Outcome Measures / Patients / PD-L1 protein / Pembrolizumab / Placebos / Progression-Free Survival / Radiation therapy / Statistical analysis / Survival Analysis / Targeted cancer therapy / Treatments in Oncology / Tumor cells / Tumors / Uterine Cervical Neoplasms - drug therapy / Uterine Cervical Neoplasms - mortality / Uterine Cervical Neoplasms - pathology

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

2021

Confirm

Do you wish to request the book?

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Shapira-Frommer, Ronnie,

Arkhipov, Alexander,

Colombo, Nicoletta,

Monk, Bradley J,

Li, Kan,

Salman, Pamela,

Dubot, Coraline,

Samouëlian, Vanessa,

Castonguay, Vincent,

Caceres, M. Valeria,

Yañez, Eduardo,

Olivera Hurtado de Mendoza, Mivael,

Toker, Sarper,

Hoyos Usta, Edwin,

Tewari, Krishnansu S,

Gümüş, Mahmut,

Hasegawa, Kosei,

Keefe, Stephen M,

Lorusso, Domenica

2021

Overview

A randomized, double-blind trial compared pembrolizumab with placebo in patients with advanced cervical cancer who were also receiving platinum-based chemotherapy with or without bevacizumab. The median progression-free survival was 10.4 months with pembrolizumab and 8.2 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Adverse events

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - therapeutic use

/ Antineoplastic Agents, Immunological - adverse effects